JP2022521208A5 - - Google Patents

Info

Publication number
JP2022521208A5
JP2022521208A5 JP2021548233A JP2021548233A JP2022521208A5 JP 2022521208 A5 JP2022521208 A5 JP 2022521208A5 JP 2021548233 A JP2021548233 A JP 2021548233A JP 2021548233 A JP2021548233 A JP 2021548233A JP 2022521208 A5 JP2022521208 A5 JP 2022521208A5
Authority
JP
Japan
Prior art keywords
nri
pharmaceutical composition
maoi
composition according
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021548233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521208A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018567 external-priority patent/WO2020168337A1/en
Publication of JP2022521208A publication Critical patent/JP2022521208A/ja
Publication of JP2022521208A5 publication Critical patent/JP2022521208A5/ja
Pending legal-status Critical Current

Links

JP2021548233A 2019-02-17 2020-02-18 うつ病及び他の障害の治療のための組成物及び方法 Pending JP2022521208A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806831P 2019-02-17 2019-02-17
US62/806,831 2019-02-17
PCT/US2020/018567 WO2020168337A1 (en) 2019-02-17 2020-02-18 Compositions and methods for treatment of depression and other disorders

Publications (2)

Publication Number Publication Date
JP2022521208A JP2022521208A (ja) 2022-04-06
JP2022521208A5 true JP2022521208A5 (enExample) 2023-03-01

Family

ID=72045151

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021548233A Pending JP2022521208A (ja) 2019-02-17 2020-02-18 うつ病及び他の障害の治療のための組成物及び方法

Country Status (7)

Country Link
US (1) US12465611B2 (enExample)
EP (1) EP3923919A4 (enExample)
JP (1) JP2022521208A (enExample)
CN (1) CN113631157A (enExample)
AU (2) AU2020223284A1 (enExample)
CA (1) CA3130580A1 (enExample)
WO (1) WO2020168337A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL324976A (en) * 2023-06-16 2026-01-01 Neurawell Therapeutics Combination treatments for depression and other disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999382A (en) 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20040102440A1 (en) 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
EP1715843A1 (en) 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
EP1737473A4 (en) 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
EP1879574A2 (en) 2005-02-23 2008-01-23 Prexa Pharmaceuticals, Inc. Multimediator 5-ht6 receptor antagonists, and uses related thereto
CN101163477A (zh) 2005-02-23 2008-04-16 普雷萨药品公司 多介质多巴胺转运抑制剂，以及其相关应用
CN102343084A (zh) 2005-03-31 2012-02-08 安米林药品公司 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
CA2604915A1 (en) 2005-04-22 2006-11-02 Wyeth New therapeutic combinations for the treatment or prevention of depression
WO2006116165A1 (en) 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
EP1998773A2 (en) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware New therapeutic combinations for the treatment of depression
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
ES2500053T3 (es) * 2007-03-09 2014-09-29 Chelsea Therapeutics, Inc. Composición farmacéutica que comprende droxidopa para el tratamiento de la fibromialgia
JP2010526820A (ja) * 2007-05-07 2010-08-05 チェルシー・セラピューティクス，インコーポレイテッド 気分障害、睡眠障害、または注意欠陥障害を治療するドロキシドパおよびその医薬組成物
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
ES2689520T3 (es) 2010-04-23 2018-11-14 Kempharm, Inc. Formulación terapéutica para reducir los efectos secundarios de fármacos
WO2012048243A2 (en) 2010-10-08 2012-04-12 University Of Utah Research Foundation Depression disorder therapeutics with creatine analogs
US20130217673A1 (en) * 2012-02-22 2013-08-22 Warsaw Orthopedic, Inc Mixed monoamine reuptake inhibitor in a biodegradable polymer carrier
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
WO2014120936A2 (en) 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
MD3426251T2 (ro) 2016-03-10 2022-09-30 Janssen Pharmaceutica Nv Metode de tratament al depresiei utilizând antagoniști ai receptorului orexină-2
US10624939B2 (en) 2017-05-23 2020-04-21 Luke Klele Natural product compositions for treating or managing symptoms of ADD, ADHD, anxiety, and depression
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
CN111233737B (zh) 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途

Similar Documents

Publication Publication Date Title
EP1492519B1 (en) Methods for treating lower urinary tract disorders using antimuscarinics and alpha-2-delta subunit calcium channel modulators
JP2009511618A (ja) 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用
HU225534B1 (en) Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors
HUE029677T2 (hu) Készítmények centrálisan mediált émelygés és hányás kezelésére
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
RU97103563A (ru) Композиции длительного высвобождения венлафаксин гидрохлорида, композиция пленочного покрытия, способ обеспечения терапевтически активной концентрации венлафаксина и способ исключения нулевых и пиковых концентраций лекарственного средства
JP2024540183A5 (enExample)
SK14612003A3 (sk) Použitie enantiomérne čistého escitalopramu a farmaceutický prostriedok s obsahom escitalopramu
RU2004105263A (ru) Фармацевтические композиции, содержащие тербинафин, и их применение
JP2020522560A5 (enExample)
EP4520394A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
CZ291941B6 (cs) Farmaceutické kombinace obsahující tramadol
JP2013536837A5 (enExample)
JP2024517085A5 (enExample)
JP2023546140A5 (enExample)
JP2022521208A5 (enExample)
EP1896076A2 (en) Compositions and methods for enhancement of sexual function
EP4494700A3 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
JP2021530568A5 (enExample)
US20110117070A1 (en) Compositions and methods for treating headache
JP2024506041A5 (enExample)
JP7312286B2 (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体
WO2020168337A4 (en) Compositions and methods for treatment of depression and other disorders
UA112652C2 (uk) Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції